BIOMEDICA DIAGNOSTICS Canada

Canadian IVD company with core competencies in the fields of Thrombosis, Haemostasis and oncology, with innovative technologies, we collaborate internationally with technology development companies and health-care stakeholders to develop and manufacture customized reagents and diagnostic solutions.
Company Size (Fulltime employees)
Year of foundation
1999
Please specify your partnering goal
Find a Partner in oncology and / or Thrombosis & Haemostasis
Headquartner in China
Plan in China
Find a Partner in China interested in marketing special Thrombosis & Haemostasis tests, and Femtelle in oncology.
Biotech/Pharma Asset Stage
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
FEMTELLE|FEMTELLE® is intended for the quantitative measurement of human Urokinase-type Plasminogen Activator (uPA) and human Plasminogen Activator Inhibitor Type-1 (PAI-1) in detergent extracts of breast tumor tissue. uPA and PAI-1 are clinically validated independent prognostic markers in breast cancer and have reached the highest Level of Evidence (LoE-1) according to the “Tumor Marker Utility System”.|MARKETED|NONE
Medtech Development Stage
ENRIQUE SANCHEZ
Mr. 
Functionality

Carmel Diagnostics ltd. Israel

Carmel Diagnostics is a medtech company who developed an innovative method for measuring Oxidative Stress (OS) of a biological liquid, a recognized biomarker of health and disease and a key diagnostics parameter. This OS parameter is measured by TCL (ThermoChemiLuminescence), an advanced yet simple technology. Carmel’s lead product is Embryo Selection in IVF process. Carmel won the prestigious Phase-2 grant from Horizon2020, planning market launch in H1/2021. It has an experienced, motivated team.

Company Size (Fulltime employees)
Year of foundation
2009
Please specify your partnering goal
Potential licensing
Funding Status
Series A, looking for an investment of 4M USD
Now raising (In USD)
5M
Headquartner in China
Plan in China
We have already registered WFOE in China. Our plans are:Establish Manufacturing site and customer support in ChinaFertissimo distribution in China to improve IVF performancePromote Additional applications in cooperation with Chinese Institutes/Academy/IndustryPromote the use of AI, Bioinformatics and machine learning for optimization and continuous improvement
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
Fertissimo TCL Analyzer. CE Mark
Medtech Development Stage
Slides Deck
(pptx, 7.32MB)
Mr Tzali Cnaani
LinkedIn logo CEO 
Functionality

Consulate General of Canada in Shanghai China

For more than 120 years, the Trade Commissioner Service (TCS) has been helping Canadian companies navigate international markets. Our trade commissioners in more than 160 cities worldwide can provide you with key business insights and access to an unbeatable network of international contacts. The TCS provides Canadian businesses and organizations with tailored advice to help them enter new markets outside of Canada.
Lulu Mi
Life Sciences Trade Commissioner 
Functionality

GATTACO Inc. United States

GattaCo is a Southern California start-up that has developed disruptive new technologies and products solving billion dollar bottlenecks in healthcare. These include its A-PON™ and Pediatric mini-PON™ Kits, which are self-contained, fully-automatic and disposable centrifuge replacement tools. The PON devices are used to extract a precise volume of antibody-rich plasma from a few drops of finger-stick capillary blood so that the plasma can be dispensed into a rapid diagnostic testing platform, such as a rapid COVID-19 antibody test, or into a tube for shipping liquid plasma to a clinical lab for analysis. The mini-PON device eliminates the need for a venipuncture for pediatric blood testing. The availability of liquid plasma for clinical lab processing, collected and processed remotely, greatly simplifies lab workflow compared to dried blood sample processing and provides a more consistent and stable sample for high-sensitivity and high-throughput serological testing. When used in conjunction with rapid antibody tests, the PON devices can provide more consistent, higher-sensitivity and quantitative results compared to the same volume of whole blood, and may allow clinically significant rapid tests to be performed in Point of Care settings.
Company Size (Fulltime employees)
Year of foundation
2018
Please specify your partnering goal
Partnership, collaboration, JV, in-licensing diagnostic technology or OEM
Funding Status
Series A 1Q21
Now raising (In USD)
US$ 10 million
Headquartner in China
Biotech/Pharma Category
Medtech Category
Medtech Information 1, Device Name|Description|Development Stage|Licensed Countries
A-PON(TM) Kit|Home sample collection kit delivering liquid plasma to the lab|commercial|
Medtech Information 2
mini-PON(TM) Kit|Pediatric blood sample collection and processing|under development|
Medtech Development Stage
Michael McNeely
LinkedIn logo Pres/CEO 
Functionality

MAVIE Technologies China

Investment banking boutique specialized in cross-border medical device transactions.
We would like to bring to your next events exclusive opportunities from Western companies in the fields of: robotics, cancer screening, liver disease diagnostic, robotics, cardiovascular and respiratory
Olivier D ARROS
Managing Partner 
Functionality